Skip to main content

Table 2 Demographic and baseline characteristics—52-week Open Label Extension

From: First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

Number of subjects

AAB-003

 

0.5 mg/kg (N = 6)

1 mg/kg (N = 3)

2 mg/kg (N = 12)

4 mg/kg (N = 10)

8 mg/kg (N = 12)

Placebo to AAB-003 (N = 9)*

Age (years), mean (SD)

65.2 (6.5)

63.0 (7.8)

68.8 (10.6)

71.3 (8.8)

60.7 (5.8)

71.7 (7.9)

Sex, n

      

 Male

2

1

2

5

4

5

 Female

4

2

10

5

8

4

Ethnicity n

      

 White

4

1

2

1

3

4

 Black

2

2

0

0

2

0

 Asian

0

0

10

9

7

5

Weight (kg), mean (SD)

71.8 (13.7)

80.0 (26.2)

54.0 (8)

65.0 (12.8)

69.9 (18.0)

66.7 (22.3)

MMSE, mean (SD)

24.7 (1.86)

21.0 (4.36)

19.3 (5.05)

18.5 (4.86)

21.3 (5.40)

18.9 (5.64)

  1. *Number of placebo subjects who transitioned to AAB-003 in the open label extension: 1 at 0.5 mg/kg, 1 at 1 mg/kg, 3 at 2 mg/kg, 1 at 4 mg/kg, and 3 at 8 mg/kg. MMSE Mini-Mental State Exam, SD Standard deviation
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193